Allergy Therapeutics (Allergy Therapeutics) Additional Paid-In Capital : $195.79 Mil(As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Additional Paid-In Capital?

Allergy Therapeutics's quarterly additional paid-in capital increased from Dec. 2022 ($144.98 Mil) to Jun. 2023 ($150.29 Mil) and increased from Jun. 2023 ($150.29 Mil) to Dec. 2023 ($195.79 Mil).

Allergy Therapeutics's annual additional paid-in capital declined from Jun. 2021 ($157.89 Mil) to Jun. 2022 ($138.64 Mil) but then increased from Jun. 2022 ($138.64 Mil) to Jun. 2023 ($150.29 Mil).

Allergy Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Allergy Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Additional Paid-In Capital Chart

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Additional Paid-In Capital

Get a 7-Day Free Trial

142.68

140.90

157.89

138.64

150.29

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															149.70	138.64	144.98	150.29	195.79

Allergy Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Allergy Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (Allergy Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

AGY:UK HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.